GTx Closer To Filing NDA For Acapodene With Promising Phase III Results
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Reduced vertebral fracture risk means the selective androgen receptor modulator could offer median survival improvement
You may also be interested in...
GTx Files Toremifene For Prostate Cancer-Related Bone Loss
GTx is looking to be first to market with a treatment for prostate cancer patients that helps prevent common and debilitating fractures caused by androgen deprivation therapy.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.